From Diabetes Care to Heart Failure Management: A Potential Therapeutic Approach Combining SGLT2 Inhibitors and Plant Extracts

Nutrients. 2022 Sep 10;14(18):3737. doi: 10.3390/nu14183737.


Diabetes is a complex chronic disease, and among the affected patients, cardiovascular disease (CVD)is the most common cause of death. Consequently, the evidence for the cardiovascular benefit of glycaemic control may reduce long-term CVD rates. Over the years, multiple pharmacological approaches aimed at controlling blood glucose levels were unable to significantly reduce diabetes-related cardiovascular events. In this view, a therapeutic strategy combining SGLT2 inhibitors and plant extracts might represent a promising solution. Indeed, countering the main cardiometabolic risk factor using plant extracts could potentiate the cardioprotective action of SGLT2 inhibitors. This review highlights the main molecular mechanisms underlying these beneficial effects that could contribute to the better management of diabetic patients.

Keywords: SGLT2 inhibitors; cardiovascular risk; diabetes; inflammation; insulin resistance; lipid accumulation; nutraceutical supplementation; reactive oxygen species (ROS).

Publication types

  • Review

MeSH terms

  • Blood Glucose
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / prevention & control
  • Diabetes Mellitus, Type 2*
  • Heart Failure* / drug therapy
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Sodium-Glucose Transporter 2 / therapeutic use
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use


  • Blood Glucose
  • Hypoglycemic Agents
  • Plant Extracts
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors